Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Unknown 2Recruiting 2

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Sarcoma 3

Conditions

Breast Neoplasms 5004Neoplasms 4197Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2265Colorectal Neoplasms 2053Lung Neoplasms 1705Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1382Neoplasm Metastasis 1374Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1192Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 895Brain Neoplasms 876Stomach Neoplasms 857Recurrence 853Carcinoma, Hepatocellular 846Glioblastoma 841Lymphoma, Large B-Cell, Diffuse 771Rectal Neoplasms 759Uterine Cervical Neoplasms 728Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

vandetanib 1pazopanib 16-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × GIST × Clear all
NCT02015065 2020-03-30

Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
9 enrolled 14 charts
Sarcoma

GIST

NCT01323400 2016-02-25

PAZOGIST

Centre Leon Berard

Phase 2 Completed
81 enrolled
Sarcoma

GIST

NCT00618319 2015-10-02

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

Biogen

Phase 2 Completed
20 enrolled
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡